Drug Type Fecal microbiota transplantation |
Synonyms- |
Target- |
Action modulators |
Mechanism Bacteria replacements, Microbiome modulators |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Constipation | Phase 2 | United States | 02 Apr 2025 | |
Scleroderma, Systemic | Phase 2 | United States | 02 Apr 2025 | |
Metabolic dysfunction-associated steatotic liver disease | Phase 2 | - | 01 Dec 2023 | |
Colitis, Ulcerative | Phase 2 | United States | 14 Sep 2020 | |
Clostridium difficile infection | Phase 2 | United States | 21 Dec 2017 | |
Parkinson Disease | Phase 2 | - | 15 Jul 2017 | |
HIV Infections | Phase 1 | United States | 12 Apr 2018 | |
Parkinson Disease | Phase 1 | - | 15 Jul 2017 |
Not Applicable | 12 | isqsafpihg(mrezaiczrq) = emmdpmvwcf rsmxbaaoch (crhamcqlux ) View more | - | 17 Sep 2021 | |||
Phase 2 | 17 | Low fecal microbiota dose (Low Fecal Microbiota Dose) | ibzhmcdsmg(hkwmlpokmk) = pxplaqbmxp bkwqjshcxw (puxhghirnh, szilpdxjcd - phitscghpw) View more | - | 06 Mar 2020 | ||
Mid fecal microbiota dose (Mid Fecal Microbiota Dose) | ibzhmcdsmg(hkwmlpokmk) = spskoppztv bkwqjshcxw (puxhghirnh, srclqsojci - mvqfgzznuk) View more |